|
US2020397767A1
|
|
Stable pharmaceutical product and vessel comprising sodium picosulfate, magnesium oxide and citric acid
|
|
WO2020165741A1
|
|
Novel triterpene derivatives as hiv inhibitors
|
|
WO2020165742A1
|
|
Novel triterpenone derivatives as hiv inhibitors
|
|
US2020078309A1
|
|
Stable tablet compositions of Sacubitril: Valsartan
|
|
US2019336478A1
|
|
Stable oral liquid compositions of enalapril
|
|
WO2019207517A1
|
|
Process for preparation of ((3r,11br)-1,3,4,6,7,11b-hexahydro-9,10-di(methoxy-d 3)-3-(2-methylpropyl)-2h-benzo[a]quinolizin-2-one
|
|
WO2019130341A1
|
|
Capsule compositions comprising lopinavir and ritonavir
|
|
US2019290588A1
|
|
Stable bilayer tablet compositions
|
|
US2018280364A1
|
|
Pharmaceutical compositions of sodium picosulfate, magnesium oxide and citric acid
|
|
WO2018069857A1
|
|
C-3 novel triterpenone with c-17 reverse amide heterocycle derivatives as hiv inhibitors
|
|
WO2018078644A1
|
|
Orally disintegrating tablets of eltrombopag
|
|
WO2018065930A1
|
|
C-3 triterpenone with c-17 reverse amide derivatives as hiv inhibitors
|
|
WO2018029610A1
|
|
C-3 novel triterpenone with c-17 n-amide derivatives as hiv inhibitors
|
|
WO2018029604A1
|
|
C-3 novel triterpenone with c-17 reverse amide derivatives as hiv inhibitors
|
|
WO2018029602A1
|
|
C-3 novel triterpenone with c-28 heterocycle derivatives as hiv inhibitors
|
|
WO2018025247A1
|
|
C-3 novel triterpenone with c-28 diamide derivatives as hiv inhibitors
|
|
EP3496719A1
|
|
A multi-class anti-retroviral composition
|
|
US2019175509A1
|
|
High Drug Loaded Tablet Composition for Treating HIV
|
|
US2019175508A1
|
|
Anti-retroviral compositions
|
|
WO2017149518A1
|
|
C-3 novel triterpene with c-17 amine derivatives as hiv inhibitors
|
